Abdullah Rasheed
@dr-rasheed.bsky.social
Clinical Observer at Nephrology- Hattiesburg Clinic, MS
2026 IM Residency Match Applicant
2026 IM Residency Match Applicant
Reposted by Abdullah Rasheed
Ok, sometimes creativity makes for strange associations…
I’ve seen the memes of the Banksy guy throwing a sandwich, and I’m working on art for #KidneyWeek25… so I give you: #Kidneyeet , a faster path to transplant 🤷 #NephSky
I’ve seen the memes of the Banksy guy throwing a sandwich, and I’m working on art for #KidneyWeek25… so I give you: #Kidneyeet , a faster path to transplant 🤷 #NephSky
August 25, 2025 at 12:44 AM
Ok, sometimes creativity makes for strange associations…
I’ve seen the memes of the Banksy guy throwing a sandwich, and I’m working on art for #KidneyWeek25… so I give you: #Kidneyeet , a faster path to transplant 🤷 #NephSky
I’ve seen the memes of the Banksy guy throwing a sandwich, and I’m working on art for #KidneyWeek25… so I give you: #Kidneyeet , a faster path to transplant 🤷 #NephSky
😅 This demand was intense but at the end it worked out for him!
# NephJC
# NephJC
Is it time to formally test this combination therapy in a dedicated outcomes trial ❓#NephJC
July 9, 2025 at 1:59 AM
😅 This demand was intense but at the end it worked out for him!
# NephJC
# NephJC
Reposted by Abdullah Rasheed
T3m #NephJC
But here’s the flip side
✅internal validity was strong
✅nearly all participants (98.4%) were on maximally tolerated ACEi/ARB
✅high Asian representation (46%) - important given Asia’s large population and unique risk profile for diabetes-related complications❗️
But here’s the flip side
✅internal validity was strong
✅nearly all participants (98.4%) were on maximally tolerated ACEi/ARB
✅high Asian representation (46%) - important given Asia’s large population and unique risk profile for diabetes-related complications❗️
July 9, 2025 at 1:53 AM
T3m #NephJC
But here’s the flip side
✅internal validity was strong
✅nearly all participants (98.4%) were on maximally tolerated ACEi/ARB
✅high Asian representation (46%) - important given Asia’s large population and unique risk profile for diabetes-related complications❗️
But here’s the flip side
✅internal validity was strong
✅nearly all participants (98.4%) were on maximally tolerated ACEi/ARB
✅high Asian representation (46%) - important given Asia’s large population and unique risk profile for diabetes-related complications❗️
Reposted by Abdullah Rasheed
T3j #NephJC
Guidelines suggest stepwise Rx based on UACR response
But in practice? It often means clinical inertia
👉 Most clinicians won’t recheck UACR in a timely manner
👉 Patients miss the window for intensification
👉 Disease silently progresses
Guidelines suggest stepwise Rx based on UACR response
But in practice? It often means clinical inertia
👉 Most clinicians won’t recheck UACR in a timely manner
👉 Patients miss the window for intensification
👉 Disease silently progresses
July 9, 2025 at 1:50 AM
T3j #NephJC
Guidelines suggest stepwise Rx based on UACR response
But in practice? It often means clinical inertia
👉 Most clinicians won’t recheck UACR in a timely manner
👉 Patients miss the window for intensification
👉 Disease silently progresses
Guidelines suggest stepwise Rx based on UACR response
But in practice? It often means clinical inertia
👉 Most clinicians won’t recheck UACR in a timely manner
👉 Patients miss the window for intensification
👉 Disease silently progresses
Reposted by Abdullah Rasheed
T3g #NephJC
UACR proved useful in this trial
👉it showed a sustained reduction with combination therapy and stabilization of eGFR
Extending the trial might have been unethical, as it would delay optimal therapy
UACR proved useful in this trial
👉it showed a sustained reduction with combination therapy and stabilization of eGFR
Extending the trial might have been unethical, as it would delay optimal therapy
July 9, 2025 at 1:47 AM
T3g #NephJC
UACR proved useful in this trial
👉it showed a sustained reduction with combination therapy and stabilization of eGFR
Extending the trial might have been unethical, as it would delay optimal therapy
UACR proved useful in this trial
👉it showed a sustained reduction with combination therapy and stabilization of eGFR
Extending the trial might have been unethical, as it would delay optimal therapy
Reposted by Abdullah Rasheed
T3f #NephJC
UACR is now considered a validated surrogate for CKD progression in trials
So while CONFIDENCE didn’t study hard outcomes… this degree of albuminuria reduction probably means long-term benefit
Agree or too soon to tell?
UACR is now considered a validated surrogate for CKD progression in trials
So while CONFIDENCE didn’t study hard outcomes… this degree of albuminuria reduction probably means long-term benefit
Agree or too soon to tell?
July 9, 2025 at 1:46 AM
T3f #NephJC
UACR is now considered a validated surrogate for CKD progression in trials
So while CONFIDENCE didn’t study hard outcomes… this degree of albuminuria reduction probably means long-term benefit
Agree or too soon to tell?
UACR is now considered a validated surrogate for CKD progression in trials
So while CONFIDENCE didn’t study hard outcomes… this degree of albuminuria reduction probably means long-term benefit
Agree or too soon to tell?
Reposted by Abdullah Rasheed
T3e #NephJC
Meta-analyses show 30% UACR drop = ~27% ↓ in major kidney events (ESKD, doubling Cr, eGFR <15)
👉 Regardless of intervention (RASi/SGLT2i/MRA)
pubmed.ncbi.nlm.nih....
CONFIDENCE cut UACR by 52%.
That’s hard to ignore
Meta-analyses show 30% UACR drop = ~27% ↓ in major kidney events (ESKD, doubling Cr, eGFR <15)
👉 Regardless of intervention (RASi/SGLT2i/MRA)
pubmed.ncbi.nlm.nih....
CONFIDENCE cut UACR by 52%.
That’s hard to ignore
July 9, 2025 at 1:45 AM
T3e #NephJC
Meta-analyses show 30% UACR drop = ~27% ↓ in major kidney events (ESKD, doubling Cr, eGFR <15)
👉 Regardless of intervention (RASi/SGLT2i/MRA)
pubmed.ncbi.nlm.nih....
CONFIDENCE cut UACR by 52%.
That’s hard to ignore
Meta-analyses show 30% UACR drop = ~27% ↓ in major kidney events (ESKD, doubling Cr, eGFR <15)
👉 Regardless of intervention (RASi/SGLT2i/MRA)
pubmed.ncbi.nlm.nih....
CONFIDENCE cut UACR by 52%.
That’s hard to ignore
Reposted by Abdullah Rasheed
July 9, 2025 at 1:44 AM
This is huge!
#NephJC
#NephJC
T3a #NephJC
The results are packed so let’s do a full dive into the discussion
The big picture? 🔍
Combo therapy with finerenone + empagliflozin led to a 52% reduction in albuminuria over 180 days.
That’s 32% better than empa alone, and ~29% better than finerenone alone
A full additive effect!
The results are packed so let’s do a full dive into the discussion
The big picture? 🔍
Combo therapy with finerenone + empagliflozin led to a 52% reduction in albuminuria over 180 days.
That’s 32% better than empa alone, and ~29% better than finerenone alone
A full additive effect!
July 9, 2025 at 1:42 AM
This is huge!
#NephJC
#NephJC
Reposted by Abdullah Rasheed
T2n #NephJC
AKI events were few, and hyperkalemia-related discontinuation was rare (just 1 per group).
Honestly - nothing wildly unexpected or unmanageable. Would you agree?
AKI events were few, and hyperkalemia-related discontinuation was rare (just 1 per group).
Honestly - nothing wildly unexpected or unmanageable. Would you agree?
July 9, 2025 at 1:39 AM
T2n #NephJC
AKI events were few, and hyperkalemia-related discontinuation was rare (just 1 per group).
Honestly - nothing wildly unexpected or unmanageable. Would you agree?
AKI events were few, and hyperkalemia-related discontinuation was rare (just 1 per group).
Honestly - nothing wildly unexpected or unmanageable. Would you agree?
Reposted by Abdullah Rasheed
T2a: RESULTS
Here comes the exciting part! Let’s breakdown the results
🔍 1664 screened → 818 randomized
⚖️ Final analysis: 800 participants (Combo: 269, Finerenone: 264, Empagliflozin: 267)
💊 Safety analysis: 798 took at least 1 dose
📅 Last follow-up: March 2025
#NephJC
Here comes the exciting part! Let’s breakdown the results
🔍 1664 screened → 818 randomized
⚖️ Final analysis: 800 participants (Combo: 269, Finerenone: 264, Empagliflozin: 267)
💊 Safety analysis: 798 took at least 1 dose
📅 Last follow-up: March 2025
#NephJC
July 9, 2025 at 1:26 AM
T2a: RESULTS
Here comes the exciting part! Let’s breakdown the results
🔍 1664 screened → 818 randomized
⚖️ Final analysis: 800 participants (Combo: 269, Finerenone: 264, Empagliflozin: 267)
💊 Safety analysis: 798 took at least 1 dose
📅 Last follow-up: March 2025
#NephJC
Here comes the exciting part! Let’s breakdown the results
🔍 1664 screened → 818 randomized
⚖️ Final analysis: 800 participants (Combo: 269, Finerenone: 264, Empagliflozin: 267)
💊 Safety analysis: 798 took at least 1 dose
📅 Last follow-up: March 2025
#NephJC
T2a: RESULTS
Here comes the exciting part! Let’s breakdown the results
🔍 1664 screened → 818 randomized
⚖️ Final analysis: 800 participants (Combo: 269, Finerenone: 264, Empagliflozin: 267)
💊 Safety analysis: 798 took at least 1 dose
📅 Last follow-up: March 2025
#NephJC
Here comes the exciting part! Let’s breakdown the results
🔍 1664 screened → 818 randomized
⚖️ Final analysis: 800 participants (Combo: 269, Finerenone: 264, Empagliflozin: 267)
💊 Safety analysis: 798 took at least 1 dose
📅 Last follow-up: March 2025
#NephJC
July 9, 2025 at 1:28 AM
Reposted by Abdullah Rasheed
T1e #NephJC
Participants had 7 prespecified visits with:
— UACR measured from 2 consecutive morning urines (3 at screening!)
— Labs for K & eGFR
— 3 BP readings after ≥5 min rest
Treatment stopped at Day 180, but checked UACR, BP, K⁺ & eGFR again at Day 210
Rigorous enough for you?
Participants had 7 prespecified visits with:
— UACR measured from 2 consecutive morning urines (3 at screening!)
— Labs for K & eGFR
— 3 BP readings after ≥5 min rest
Treatment stopped at Day 180, but checked UACR, BP, K⁺ & eGFR again at Day 210
Rigorous enough for you?
July 9, 2025 at 1:21 AM
T1e #NephJC
Participants had 7 prespecified visits with:
— UACR measured from 2 consecutive morning urines (3 at screening!)
— Labs for K & eGFR
— 3 BP readings after ≥5 min rest
Treatment stopped at Day 180, but checked UACR, BP, K⁺ & eGFR again at Day 210
Rigorous enough for you?
Participants had 7 prespecified visits with:
— UACR measured from 2 consecutive morning urines (3 at screening!)
— Labs for K & eGFR
— 3 BP readings after ≥5 min rest
Treatment stopped at Day 180, but checked UACR, BP, K⁺ & eGFR again at Day 210
Rigorous enough for you?
Reposted by Abdullah Rasheed
T1d #NephJC
It wasn’t just random… It was stratified by eGFR (<60 vs ≥60) and UACR (≤850 vs >850 mg/g) to keep the groups balanced in terms of kidney function and albuminuria severity.
The trial was triple blinded– participants, investigators, and assessors
It wasn’t just random… It was stratified by eGFR (<60 vs ≥60) and UACR (≤850 vs >850 mg/g) to keep the groups balanced in terms of kidney function and albuminuria severity.
The trial was triple blinded– participants, investigators, and assessors
July 9, 2025 at 1:20 AM
T1d #NephJC
It wasn’t just random… It was stratified by eGFR (<60 vs ≥60) and UACR (≤850 vs >850 mg/g) to keep the groups balanced in terms of kidney function and albuminuria severity.
The trial was triple blinded– participants, investigators, and assessors
It wasn’t just random… It was stratified by eGFR (<60 vs ≥60) and UACR (≤850 vs >850 mg/g) to keep the groups balanced in terms of kidney function and albuminuria severity.
The trial was triple blinded– participants, investigators, and assessors
Reposted by Abdullah Rasheed
T1c #NephJC
Randomization was 1:1:1 — finerenone alone (10 or 20 mg), empagliflozin alone (10 mg), or both together
Finerenone dose was based on eGFR:
• eGFR ≥60 → 20 mg
• eGFR <60 → 10 mg
Randomization was 1:1:1 — finerenone alone (10 or 20 mg), empagliflozin alone (10 mg), or both together
Finerenone dose was based on eGFR:
• eGFR ≥60 → 20 mg
• eGFR <60 → 10 mg
July 9, 2025 at 1:19 AM
T1c #NephJC
Randomization was 1:1:1 — finerenone alone (10 or 20 mg), empagliflozin alone (10 mg), or both together
Finerenone dose was based on eGFR:
• eGFR ≥60 → 20 mg
• eGFR <60 → 10 mg
Randomization was 1:1:1 — finerenone alone (10 or 20 mg), empagliflozin alone (10 mg), or both together
Finerenone dose was based on eGFR:
• eGFR ≥60 → 20 mg
• eGFR <60 → 10 mg
Reposted by Abdullah Rasheed
July 9, 2025 at 1:18 AM
Reposted by Abdullah Rasheed
T0g #NephJC
And that’s where the CONFIDENCE trial steps in
👉It tested whether finerenone + empagliflozin reduces UACR more than either alone — and if starting both together is safe
Turning whispers into a bold headline: More patients. Longer duration. Greater statistical power ❗️
And that’s where the CONFIDENCE trial steps in
👉It tested whether finerenone + empagliflozin reduces UACR more than either alone — and if starting both together is safe
Turning whispers into a bold headline: More patients. Longer duration. Greater statistical power ❗️
July 9, 2025 at 1:15 AM
T0g #NephJC
And that’s where the CONFIDENCE trial steps in
👉It tested whether finerenone + empagliflozin reduces UACR more than either alone — and if starting both together is safe
Turning whispers into a bold headline: More patients. Longer duration. Greater statistical power ❗️
And that’s where the CONFIDENCE trial steps in
👉It tested whether finerenone + empagliflozin reduces UACR more than either alone — and if starting both together is safe
Turning whispers into a bold headline: More patients. Longer duration. Greater statistical power ❗️
Reposted by Abdullah Rasheed
A post hoc analysis comparing finerenone (FIDELIO/FIGARO) and canagliflozin (CREDENCE) showed similar magnitudes of cardiorenal risk reduction
👉 pubmed.ncbi.nlm.nih....
That’s big — especially considering how different the trial designs were!
Any thoughts?
👉 pubmed.ncbi.nlm.nih....
That’s big — especially considering how different the trial designs were!
Any thoughts?
July 9, 2025 at 1:12 AM
A post hoc analysis comparing finerenone (FIDELIO/FIGARO) and canagliflozin (CREDENCE) showed similar magnitudes of cardiorenal risk reduction
👉 pubmed.ncbi.nlm.nih....
That’s big — especially considering how different the trial designs were!
Any thoughts?
👉 pubmed.ncbi.nlm.nih....
That’s big — especially considering how different the trial designs were!
Any thoughts?
Reposted by Abdullah Rasheed
T0b: #NephJC
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
July 9, 2025 at 1:10 AM
T0b: #NephJC
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy:
medicinetoday.com.au...
Reposted by Abdullah Rasheed
T0c #NephJC
We’ve already seen what each class can do individually:
✔️ RAAS-i: foundational therapy
✔️ SGLT2i: game-changer in EMPA-KIDNEY, DAPA-CKD
✔️ Finerenone: reduced renal and CV events in FIDELIO-DKD and FIGARO-DKD
✔️ GLP1-RA: Renal and CV benefits in FLOW
We’ve already seen what each class can do individually:
✔️ RAAS-i: foundational therapy
✔️ SGLT2i: game-changer in EMPA-KIDNEY, DAPA-CKD
✔️ Finerenone: reduced renal and CV events in FIDELIO-DKD and FIGARO-DKD
✔️ GLP1-RA: Renal and CV benefits in FLOW
July 9, 2025 at 1:11 AM
T0c #NephJC
We’ve already seen what each class can do individually:
✔️ RAAS-i: foundational therapy
✔️ SGLT2i: game-changer in EMPA-KIDNEY, DAPA-CKD
✔️ Finerenone: reduced renal and CV events in FIDELIO-DKD and FIGARO-DKD
✔️ GLP1-RA: Renal and CV benefits in FLOW
We’ve already seen what each class can do individually:
✔️ RAAS-i: foundational therapy
✔️ SGLT2i: game-changer in EMPA-KIDNEY, DAPA-CKD
✔️ Finerenone: reduced renal and CV events in FIDELIO-DKD and FIGARO-DKD
✔️ GLP1-RA: Renal and CV benefits in FLOW
Reposted by Abdullah Rasheed
🎨 Okay okay… I might have made another #visualabstract for #NephJC.
Let’s just say the mentors made creativity feel mandatory 😅
Let’s just say the mentors made creativity feel mandatory 😅
July 9, 2025 at 1:06 AM
🎨 Okay okay… I might have made another #visualabstract for #NephJC.
Let’s just say the mentors made creativity feel mandatory 😅
Let’s just say the mentors made creativity feel mandatory 😅
Reposted by Abdullah Rasheed
Reposted by Abdullah Rasheed
👉Before we start, a few reminders! Are you new to #NephJC ? Not sure what to do or how this works? Here is a quick rundown, an infographic made by
@sstoneman.bsky.social
@sstoneman.bsky.social
July 9, 2025 at 12:51 AM
👉Before we start, a few reminders! Are you new to #NephJC ? Not sure what to do or how this works? Here is a quick rundown, an infographic made by
@sstoneman.bsky.social
@sstoneman.bsky.social
Reposted by Abdullah Rasheed
⏰ Just 30 minutes left before #NephJC chat
What happens when you combine two proven kidney-protective agents? 💬
Can 1 + 1 > 2?
We’re putting it to the test… with CONFIDENCE 💥
Catch the full summary here👇
www.nephjc.com/news/...
What happens when you combine two proven kidney-protective agents? 💬
Can 1 + 1 > 2?
We’re putting it to the test… with CONFIDENCE 💥
Catch the full summary here👇
www.nephjc.com/news/...
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease — NephJC
This week, we will discuss how the CONFIDENCE trial gets nephrology closer
to the magic CKD polypill of CKD.
www.nephjc.com
July 9, 2025 at 12:30 AM
⏰ Just 30 minutes left before #NephJC chat
What happens when you combine two proven kidney-protective agents? 💬
Can 1 + 1 > 2?
We’re putting it to the test… with CONFIDENCE 💥
Catch the full summary here👇
www.nephjc.com/news/...
What happens when you combine two proven kidney-protective agents? 💬
Can 1 + 1 > 2?
We’re putting it to the test… with CONFIDENCE 💥
Catch the full summary here👇
www.nephjc.com/news/...